CESSATECH A/S DK -20 (F:8GN) — Market Cap & Net Worth
Market Cap & Net Worth: CESSATECH A/S DK -20 (8GN)
CESSATECH A/S DK -20 (F:8GN) has a market capitalization of $38.64 Million (€33.05 Million) as of June 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #22897 globally and #2013 in its home market, demonstrating a 12.08% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CESSATECH A/S DK -20's stock price €2.32 by its total outstanding shares 18576437 (18.58 Million). Review 8GN total liabilities to assess the company's total debt and financial obligations.
CESSATECH A/S DK -20 Market Cap History: 2021 to 2026
CESSATECH A/S DK -20's market capitalization history from 2021 to 2026. Data shows change from $51.58 Million to $50.39 Million (-3.67% CAGR).
CESSATECH A/S DK -20 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CESSATECH A/S DK -20's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
8.36x
CESSATECH A/S DK -20's market cap is 8.36 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2024 | $31.60 Million | $2.49 Million | -$14.67 Million | 12.71x | N/A |
| 2025 | $47.78 Million | $5.72 Million | -$10.90 Million | 8.36x | N/A |
Competitor Companies of 8GN by Market Capitalization
Companies near CESSATECH A/S DK -20 in the global market cap rankings as of June 19, 2026.
Key companies related to CESSATECH A/S DK -20 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.20 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €762.80 |
CESSATECH A/S DK -20 Historical Marketcap From 2021 to 2026
Between 2021 and today, CESSATECH A/S DK -20's market cap moved from $51.58 Million to $ 50.39 Million, with a yearly change of -3.67%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €50.39 Million | +5.45% |
| 2025 | €47.78 Million | +51.20% |
| 2024 | €31.60 Million | +85.59% |
| 2023 | €17.03 Million | +310.47% |
| 2022 | €4.15 Million | -91.96% |
| 2021 | €51.58 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of CESSATECH A/S DK -20 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $38.64 Million USD |
| MoneyControl | $38.64 Million USD |
| MarketWatch | $38.64 Million USD |
| marketcap.company | $38.64 Million USD |
| Reuters | $38.64 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About CESSATECH A/S DK -20
Cessatech A/S, a pivotal-stage pediatric biotech company, develops specialty hospital medicines for children in Denmark. Its lead candidate product is CT001, a fixed-dose nasal spray for treating acute pain in children. The company also develops CT002, a non-invasive intranasal sedation for children undergoing medical procedures in Phase 2 clinical trials; and CT003, a topical anesthetic in pre-c… Read more